Press Releases
Analyst Coverage
Annual and Interim Reports
Annual General Meeting
Conflict Minerals Disclosure
Debt Investors
Dividend
Events
Financial Highlights
Investor News
Our Strategy
Quarterly Results and Presentations
Recent Acquisitions
Shareholder Information
WHO WE ARE
Areas of Focus
Responsibility
Leadership
How We Operate
PATIENTS
Patient Resources
Patient Services
Patient Advocacy
Scholarships
R&D
Our R&D Strategy
EDUCATIONAL GRANTS
Investigator Initiated Research (IIR)
Collaborative Research (CR)
Pipeline
Clinical Trials
Collaborations
PRODUCTS
Product List
Manufacturing
Postmarketing Commitments
CAREERS
Shire and SAIIDAC announce planned delisting of notes from the New York Stock Exchange
De-listing and cancellation of trading of Shire Shares
Director/PDMR Shareholding
Scheme becomes effective
Takeda Completes Acquisition of Shire, Becoming a Global, Values-based, R&D-Driven Biopharmaceutical Leader
Holding(s) in Company
Court Sanction of the Scheme
Total Voting Rights
Rule 2.9 announcement
Rule 2.9 Announcement
Director Declaration
Form 8 (DD) – Ian Clark
Form 8 (DD) – Steven Gillis
Form 8 (DD) – Sara Matthew
Form 8 (DD) – Olivier Bohuon
Form 8 (DD) – Susan Kilsby
Form 8 (DD) – David Ginsberg
Form 8 (DD) – Gail Foster
LOAD MORE
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.